Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP).

Mansoor N Saleh, MD, Howard Liebman, MD, Zale P. Bernstein, MD, O. George Negrea, MD, James B. Bussel, MD, Anthony C. Onyegbula, DO, Charles M Farber, MD, PhD, Rashid Abassi, MD, Thomas M. Cosgriff, MD, Kenneth Pennington, MD, Heather Horne, Nick Teoh, PhD, Asraf Gomaa, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2009) 114 (22): 1322.

https://doi.org/10.1182/blood.V114.22.1322.1322

Published: 2009

Journal Articles

Subcutaneous Injections of Low Doses of Humanized Anti-CD20 Veltuzumab for Treatment of Indolent B-Cell Malignancies.

O. George Negrea, MD, Steven L Allen, Kanti R. Rai, MD, Rebecca Elstrom, MD, Rashid Abassi, MD, Charles M Farber, MD, PhD, Nick Teoh, PhD, Heather Horne, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2009) 114 (22): 3757.

https://doi.org/10.1182/blood.V114.22.3757.3757

Published: 2009

Journal Articles

Low-Dose Humanized Anti-CD20 Monoclonal Antibody (MAb), Veltuzumab, in Adult Immune Thrombocytopenic Purpura (ITP): Initial Results of a Phase I/II Study.

Howard A. Liebman, MA, MD, Mansoor N. Saleh, MD, Rashid Abassi, MD, Thomas M. Cosgriff, MD, Nick Teoh, PhD, Matthew J Leoni, MD, William Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2008) 112 (11): 3412.

https://doi.org/10.1182/blood.V112.11.3412.3412

Published: 2008

Journal Articles

First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma

Jonathan Kaufman, MD, Ruben Niesvizky, MD, Edward A. Stadtmauer, MD, Asher Chanan-Khan, MD, David Siegel, MD, PhD, Heather Horne, Nick Teoh, PhD, Matthew J. Leoni, MD, William A Wegener, MD, PhD, David M. Goldenberg, ScD, MD

Blood (2008) 112 (11): 3697.

https://doi.org/10.1182/blood.V112.11.3697.3697

Published: 2008

Journal Articles

Durable Complete Responses Following Therapy with Epratuzumab Plus Rituximab: Final Efficacy Results of a Multicenter Study in Recurrent Indolent Non-Hodgkin’s Lymphoma (NHL).

John P. Leonard, MD, Stephen J. Schuster, MD, Christos Emmanouilides, MD, Felix Couture, MD, Nick Teoh, PhD, William A. Wegener, MD, PhD, David M. Goldenberg, ScD, MD

Blood (2007) 110 (11): 3419.

https://doi.org/10.1182/blood.V110.11.3419.3419

Published: 2007

Journal Articles

Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 ( hA 20): Phase I/II Results.

Franck Morschhauser, MD, John P. Leonard, MD, Luis Fayad, MD, Bertrand Coiffier, MD, STephen J. Schuster, MD, Martin J.S. Dyer, MD, Marie-Odile Petillon, MD, Morton Coleman, MD, Amina Bahkti, Heather Horne, Li Xu, MD, Nick Teoh, PhD, William A. Wegener, MD, David M. Goldenberg, MD

Blood (2006) 108 (11): 2719.

https://doi.org/10.1182/blood.V108.11.2719.2719

Published: 2006

Journal Articles

The Follicular Lymphoma International Prognostic Index (FLIPI) Can Be a Useful Prognostic Indicator for Patients with Follicular Lymphoma Treated with Combination of Rituximab and Epratuzumab.

Sandra J. Strauss, MD, Franck Morschhauser, MD, Martin Gramatzki, MD, Philippe Solal-Celigny, MD, PhD, Pier L. Zinzani, MD, Andreas Engert, MD, Bertrand Coiffier, MD, Dieter Hoelzer, MD, PhD, Nick Teoh, PhD, William A. Wegener, MD, PhD, David M. Goldenberg, ScD, MD, Ivan D. Horak, MD, Thomas A. Lister, MD

Blood (2005) 106 (11): 4796.

https://doi.org/10.1182/blood.V106.11.4796.4796

Published: 2005

Journal Articles

Initial Safety and Efficacy Results of a Second-Generation Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Non-Hodgkin’s Lymphoma.

Franck Morschhauser, John P. Leonard, Bertrand Coiffier, Marie-Odile Petillon, Morton Coleman, Amina Bahkti, Puja Sapra, Nick Teoh, William A. Wegener, Ivan D. Horak, David M. Goldenberg

Blood (2005) 106 (11): 2428.

https://doi.org/10.1182/blood.V106.11.2428.2428

Published: 2005

NARROW

Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP).

Subcutaneous Injections of Low Doses of Humanized Anti-CD20 Veltuzumab for Treatment of Indolent B-Cell Malignancies.

Low-Dose Humanized Anti-CD20 Monoclonal Antibody (MAb), Veltuzumab, in Adult Immune Thrombocytopenic Purpura (ITP): Initial Results of a Phase I/II Study.

First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma

Durable Complete Responses Following Therapy with Epratuzumab Plus Rituximab: Final Efficacy Results of a Multicenter Study in Recurrent Indolent Non-Hodgkin’s Lymphoma (NHL).

Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 ( hA 20): Phase I/II Results.

The Follicular Lymphoma International Prognostic Index (FLIPI) Can Be a Useful Prognostic Indicator for Patients with Follicular Lymphoma Treated with Combination of Rituximab and Epratuzumab.

Initial Safety and Efficacy Results of a Second-Generation Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only